HUP9801528A3 - Use of green porphyrins for preparation of pharmaceutical compositions with immunomodulatory activity - Google Patents

Use of green porphyrins for preparation of pharmaceutical compositions with immunomodulatory activity

Info

Publication number
HUP9801528A3
HUP9801528A3 HU9801528A HUP9801528A HUP9801528A3 HU P9801528 A3 HUP9801528 A3 HU P9801528A3 HU 9801528 A HU9801528 A HU 9801528A HU P9801528 A HUP9801528 A HU P9801528A HU P9801528 A3 HUP9801528 A3 HU P9801528A3
Authority
HU
Hungary
Prior art keywords
preparation
pharmaceutical compositions
immunomodulatory activity
green porphyrins
porphyrins
Prior art date
Application number
HU9801528A
Other languages
English (en)
Original Assignee
Univ British Columbia Vancuver
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia Vancuver filed Critical Univ British Columbia Vancuver
Publication of HUP9801528A2 publication Critical patent/HUP9801528A2/hu
Publication of HUP9801528A3 publication Critical patent/HUP9801528A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F132/00—Homopolymers of cyclic compounds containing no unsaturated aliphatic radicals in a side chain, and having one or more carbon-to-carbon double bonds in a carbocyclic ring system
    • C08F132/08—Homopolymers of cyclic compounds containing no unsaturated aliphatic radicals in a side chain, and having one or more carbon-to-carbon double bonds in a carbocyclic ring system having condensed rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
HU9801528A 1995-01-17 1996-01-11 Use of green porphyrins for preparation of pharmaceutical compositions with immunomodulatory activity HUP9801528A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/374,158 US5789433A (en) 1995-01-17 1995-01-17 Green porphyrins as immunomodulators

Publications (2)

Publication Number Publication Date
HUP9801528A2 HUP9801528A2 (hu) 1998-10-28
HUP9801528A3 true HUP9801528A3 (en) 2000-02-28

Family

ID=23475554

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9801528A HUP9801528A3 (en) 1995-01-17 1996-01-11 Use of green porphyrins for preparation of pharmaceutical compositions with immunomodulatory activity

Country Status (13)

Country Link
US (2) US5789433A (hu)
EP (1) EP0794775A1 (hu)
KR (1) KR100332554B1 (hu)
CN (1) CN1198671A (hu)
AU (1) AU706796B2 (hu)
CZ (1) CZ291179B6 (hu)
FI (1) FI972952A (hu)
HU (1) HUP9801528A3 (hu)
NO (1) NO973293L (hu)
NZ (1) NZ298356A (hu)
PL (1) PL321362A1 (hu)
TW (1) TW384222B (hu)
WO (1) WO1996022090A1 (hu)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096776A (en) * 1995-01-17 2000-08-01 Qlt Phototherapeutics, Inc. Green porphyrins as immunomodulators
US6107325A (en) * 1995-01-17 2000-08-22 Qlt Phototherapeutics, Inc. Green porphyrins as immunomodulators
US5789433A (en) * 1995-01-17 1998-08-04 Quadra Logic Technologies, Inc. Green porphyrins as immunomodulators
US5834503A (en) * 1996-06-14 1998-11-10 Qlt Phototherapeutics, Inc. Methods to treat arterial plaque
WO1998052608A1 (en) * 1997-05-16 1998-11-26 Qlt Phototherapeutics, Inc. Green porphyrins as immunomodulators
CA2221912A1 (en) * 1997-11-21 1999-05-21 David Dolphin Photosensitizers with improved biodistribution and light-absorbing properties
US6428579B1 (en) * 1998-07-01 2002-08-06 Brown University Research Foundation Implantable prosthetic devices coated with bioactive molecules
US6364907B1 (en) 1998-10-09 2002-04-02 Qlt Inc. Method to prevent xenograft transplant rejection
AU2002233092A1 (en) 2001-02-15 2002-08-28 Qlt Inc. Reduction or prevention of pdt related inflammation
AU2002348477A1 (en) * 2001-05-01 2002-12-23 The General Hospital Corporation Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies
EP1401479B1 (en) * 2001-06-04 2007-04-18 The General Hospital Corporation Detection and therapy of vulnerable plaque with photodynamic compounds
US7220778B2 (en) * 2003-04-15 2007-05-22 The General Hospital Corporation Methods and devices for epithelial protection during photodynamic therapy
US7659301B2 (en) * 2003-04-15 2010-02-09 The General Hospital Corporation Methods and devices for epithelial protection during photodynamic therapy
WO2004099375A2 (en) * 2003-04-30 2004-11-18 The General Hospital Corporation Indirectly linked photosensitizer immunoconjugates, processes for the production thereof and methods of use therof
US20040220167A1 (en) * 2003-05-02 2004-11-04 Nasrollah Samiy Methods of treating neuralgic pain
US20050048109A1 (en) * 2003-08-26 2005-03-03 Ceramoptec Industries, Inc. Non-polar photosensitizer formulations for photodynamic therapy
CA2724949A1 (en) * 2007-06-27 2008-12-31 The General Hospital Corporation Method and apparatus for optical inhibition of photodynamic therapy
ES2764781T3 (es) * 2008-02-27 2020-06-04 Yeda Res And Development Company Ltd Conjugados de RGD-(bacterio)clorofila para uso en el diagnóstico de tumores que comprenden dominios necróticos
US7968127B2 (en) * 2008-07-28 2011-06-28 Winslow David E Reverse vitamin K effect via photodynamic oxidation targeted at vascular endothelium, fibrin and blood platelets
US8709400B2 (en) * 2009-07-27 2014-04-29 Washington University Inducement of organogenetic tolerance for pancreatic xenotransplant
CN103127500B (zh) * 2013-02-07 2015-05-20 中山大学 卟啉色素作为免疫佐剂和疫苗的用途
CN110201162B (zh) * 2019-06-14 2021-09-07 中山大学附属第八医院（深圳福田） 光治疗剂在打破肿瘤免疫抑制微环境中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4883790A (en) * 1987-01-20 1989-11-28 University Of British Columbia Wavelength-specific cytotoxic agents
US5283255A (en) * 1987-01-20 1994-02-01 The University Of British Columbia Wavelength-specific cytotoxic agents
US5171749A (en) * 1987-01-20 1992-12-15 University Of British Columbia Wavelength-specific cytotoxic agents
US5095030A (en) * 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
US4920143A (en) * 1987-04-23 1990-04-24 University Of British Columbia Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents
US4838852A (en) * 1987-03-27 1989-06-13 Therakos, Inc. Active specific immune suppression
US5087636A (en) * 1990-02-20 1992-02-11 University Of British Columbia Method to destroy malignant cells in mononuclear cell populations
FR2689888B1 (fr) * 1992-04-10 1994-06-10 Rhone Poulenc Rorer Sa Nouveaux derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent.
US5422362A (en) * 1993-07-29 1995-06-06 Quadra Logic Technologies, Inc. Method to inhibit restenosis
EP0804238B1 (en) * 1995-01-13 2004-09-29 QLT Inc. Method to prevent transplant rejection
US5789433A (en) * 1995-01-17 1998-08-04 Quadra Logic Technologies, Inc. Green porphyrins as immunomodulators
AU7237896A (en) * 1995-09-06 1997-03-27 Research Foundation Of The State University Of New York, The Two-photon upconverting dyes and applications

Also Published As

Publication number Publication date
JPH10512268A (ja) 1998-11-24
HUP9801528A2 (hu) 1998-10-28
PL321362A1 (en) 1997-12-08
WO1996022090A1 (en) 1996-07-25
AU706796B2 (en) 1999-06-24
TW384222B (en) 2000-03-11
NZ298356A (en) 2001-04-27
JP3574456B2 (ja) 2004-10-06
AU4381996A (en) 1996-08-07
US5789433A (en) 1998-08-04
KR100332554B1 (ko) 2002-09-27
FI972952A0 (fi) 1997-07-11
FI972952A (fi) 1997-09-10
NO973293D0 (no) 1997-07-16
CN1198671A (zh) 1998-11-11
CZ291179B6 (cs) 2003-01-15
EP0794775A1 (en) 1997-09-17
KR19980701484A (ko) 1998-05-15
US6008241A (en) 1999-12-28
NO973293L (no) 1997-09-16
CZ221397A3 (en) 1997-11-12
MX9705376A (es) 1997-10-31

Similar Documents

Publication Publication Date Title
HUP9801528A3 (en) Use of green porphyrins for preparation of pharmaceutical compositions with immunomodulatory activity
HUP9902012A3 (en) Use of porphyrin derivatives for preparing pharmaceutical compositions improving vision
HUP9601698A3 (en) Pharmaceutical composition of adiabetical activity
AP9901556A0 (en) Sulpponamide derivatives process for their preparation and their use as medicaments
ZA965866B (en) 6-Dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients
HK1001860A1 (en) I-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients
AU3265695A (en) Novel naphthyridine derivative and medicinal composition thereof
GB9402203D0 (en) Pharmaceutical formulation
IL114492A0 (en) Benzimidazole derivatives their preparation and pharmaceutical compositions containing them
HUP0202103A2 (en) 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one derivatives, their use, pharmaceutical compositions containing them, process for the preparation of the compounds and intermediates
HU9502918D0 (en) Pharmaceutical composition of antihypertriglyceridemic activity
IL115905A0 (en) Sordarin derivatives their preparation and pharmaceutical compositions containing them
IL125710A0 (en) Arylglycinamide derivatives their preparation and pharmaceutical compositions containing them
IL126271A0 (en) 2-Arylpyrazolisoquinoline and cinnolinone derivatives methods for their preparation and pharmaceutical formulations containing them
IL118410A0 (en) Substituted camptothecin derivatives their preparation and pharmaceutical compositions containing them
HUP9902805A3 (en) Use of macrocyclic bis(indolyl)-maleimide derivatives for the preparation of pharmaceutical compositions treating ocular diseases
IL113123A (en) Mono-or bicyclic compounds their preparation and pharmaceutical compositions containing them
HUP9801993A3 (en) Ascomycin derivatives and their use for preparation of pharmaceutical compositions, process for their preparation and pharmaceutical compositions containing them
HUP9800573A3 (en) Rapamycin formulations for oral administration and process for their preparation
GB9405856D0 (en) Pharmaceutical formulation
IL123900A0 (en) New phenylamidine derivatives processes for preparing them and their use as pharmaceutical compositions
IL115125A0 (en) Pharmaceutical formulations comprising derivatives of clavulanic acid
NZ291597A (en) Carboxycyclopropan-1-yl derivatives, preparation, pharmaceutical compositions and intermediates thereof
AP9300581A0 (en) Benzofuran derivatives processes for their preparation and pharmaceutical compositions containing them and their medical use
GB9408053D0 (en) Pharmaceutical preparation